Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912076 | 0.96 | CASP2 (0.66) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL8251628 | 0.95 | CASP2 (0.63) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL24341463 | 0.93 | CASP2 (0.55) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL25574266 | 0.91 | CASP2 (0.63) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL29311189 | 0.90 | CASP2 (0.58) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL19703446 | 0.90 | CASP2 (0.58) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL12417334 | 0.90 | CASP2 (0.58) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL19703884 | 0.90 | CASP2 (0.58) | CASP2NAAAFAAHHPGDDNM1 | |
| SCHEMBL29901240 | 0.90 | CASP2 (0.58) | CASP2NAAAFAAHHPGDEPHX2 | |
| SCHEMBL30781809 | 0.88 | CASP2 (0.61) | CASP2NAAAFAAHDNM1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | CONDE-KNAPE KARIN | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172147-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS | NPY2R, NPY1R, NPY4R | CASP2 2494/4885NAAA 1877/4885FAAH 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.